Immunotherapies Set To Spark Alzheimer's Drug Market

Five late-stage Alzheimer's disease candidates, three of them monoclonal antibodies, are projected to rack up big sales when they launch, according to a new report by Datamonitor Healthcare. Like the rest of the AD drug market, growth for these products will come from treating earlier stages of the disease (article free with registration).

Sales of Alzheimer’s disease drugs across the US, Japan and five major EU markets (France, Germany, Italy, Spain and the UK) totaled $3.1 billion in 2015. By 2024, the AD market is forecast to reach $12.6 billion, a compound annual growth rate (CAGR) of 16.83%, according to "Alzheimer's Disease Forecast," a new report by Informa's Datamonitor Healthcare analyst Maha Elsayed, PhD.

The US is the largest major market for Alzheimer’s disease drugs, with an estimated 2015 value of $1.75 billion. The large US patient population and the high volume of annual...

More from Market Intelligence

More from In Vivo